AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24296748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (EXER), 60 min of cycling at 90% of the lactate threshold in the last 90 min of HD
Number of subjects: 11
Study 24296748 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased HD time of 30 min (TIME)
Number of subjects: 11
Study 24296748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (EXER)
Number of subjects: 11
Study 24296748 — intervention group
Group type: COMPARATOR
Intervention: Routine care (CONT)
Number of subjects: 11
Study 22088586 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 390
Study 22088586 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantain and Senna Granule group
Number of subjects: 390
Study 22088586 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (Acupuncture + Plantain and Senna Granule)
Number of subjects: 390
Study 19318652 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance with pain treatment intervention
Number of subjects: 401
Study 19318652 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 401
Study 17373148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetaphil Moisturizing Cream applied twice daily for 15 days on one half of the face
Number of subjects: 30
Study 17373148 — intervention group
Group type: COMPARATOR
Intervention: Untreated side of the face
Number of subjects: 30
Study 12609480 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 60 mg daily for 14 days
Number of subjects: 8
Study 12609480 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 matched postmenopausal women without MPA treatment)
Number of subjects: 8
Study 10713868 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine pre-operative chest radiograph
Number of subjects: 6111
Study 8622116 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin (15 mg/kg or 8 mg/kg once daily; 7.5 mg/kg twice daily; 4 mg/kg twice daily)
Number of subjects: 1243
Study 8622116 — intervention group
Group type: COMPARATOR
Intervention: Amikacin (7.5 mg/kg twice daily)
Number of subjects: 1243
Study 8622116 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin
Number of subjects: 1243
Study 8622116 — intervention group
Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 1243
Study 1708060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 85
Study 1708060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 85
Study 1708060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 6218099 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (16 g daily)
Number of subjects: 60
Study 6218099 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin (30 g daily)
Number of subjects: 60
Study 6742895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular steroids
Number of subjects: 42
Study 6742895 — intervention group
Group type: COMPARATOR
Intervention: Mobilisations
Number of subjects: 42
Study 6742895 — intervention group
Group type: COMPARATOR
Intervention: Ice therapy
Number of subjects: 42
Study 6742895 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 42
Study 30104867 — intervention group
Group type: EXPERIMENTAL
Intervention: High velocity resistance training (HVRT)
Number of subjects: 15
Study 30104867 — intervention group
Group type: COMPARATOR
Intervention: Traditional resistance training (RT)
Number of subjects: 15
Study 26923301 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated RBC units with potassium adsorption filter (PAF)
Number of subjects: 30
Study 26923301 — intervention group
Group type: COMPARATOR
Intervention: Standard blood infusion set (control)
Number of subjects: 30
Study 24627988 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rotation
Number of subjects: 30
Study 24627988 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 30
Study 22845178 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous whole-body vibration at 35 Hz and 4 mm amplitude
Number of subjects: 10
Study 22845178 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-alternating whole-body vibration at 26 Hz and 7.5 mm amplitude
Number of subjects: 10
Study 22845178 — intervention group
Group type: COMPARATOR
Intervention: No vibrations
Number of subjects: 10
Study 20130473 — intervention group
Group type: EXPERIMENTAL
Intervention: Connection domain mutations in HIV reverse transcriptase
Number of subjects: 345
Study 20130473 — intervention group
Group type: EXPERIMENTAL
Intervention: A371V mutation
Number of subjects: 345
Study 20130473 — intervention group
Group type: EXPERIMENTAL
Intervention: Any CD mutation
Number of subjects: 345
Study 18803951 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 54
Study 18803951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 16010204 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 391
Study 16010204 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian
Number of subjects: 391
Study 16010204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (anxiety)
Number of subjects: 391
Study 16010204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (insomnia)
Number of subjects: 391
Study 12456419 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (ISO)
Number of subjects: 56
Study 12456419 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PRO)
Number of subjects: 56
Study 10353431 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg
Number of subjects: 8
Study 10353431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8547209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (mean dose 8 mg)
Number of subjects: 223
Study 8547209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 2025078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (150,000 units every 12 hours from the start of the operation)
Number of subjects: 10
Study 2025078 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 7048826 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (200,000 Ploug units during the first 24 hours) followed by heparin (40,000 units daily for 5 days)
Number of subjects: 20
Study 7048826 — intervention group
Group type: COMPARATOR
Intervention: Heparin (40,000 units daily for 6 days)
Number of subjects: 20
Study 31163557 — intervention group
Group type: EXPERIMENTAL
Intervention: CO₂ laser
Number of subjects: 2
Study 31163557 — intervention group
Group type: COMPARATOR
Intervention: Micro-flap surgery
Number of subjects: 2
Study 28205258 — intervention group
Group type: EXPERIMENTAL
Intervention: Antofloxacin hydrochloride 200 mg IV
Number of subjects: 10
Study 26637583 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg/mL of AMB nasal irrigation daily for 2 months
Number of subjects: 77
Study 26637583 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) solution nasal irrigation daily for 2 months
Number of subjects: 77
Study 25543854 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based support (intervention group)
Number of subjects: 136
Study 25543854 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 136
Study 22908174 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg
Number of subjects: 75
Study 22908174 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 8 mg/kg
Number of subjects: 75
Study 22908174 — intervention group
Group type: COMPARATOR
Intervention: Comparator (vancomycin, teicoplanin, or semisynthetic penicillin)
Number of subjects: 75
Study 19474650 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r (darunavir/ritonavir) 600/100 mg twice daily
Number of subjects: 595
Study 17560880 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg)
Number of subjects: 80
Study 17560880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15191881 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1 mg/kg)
Number of subjects: 10
Study 15191881 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 10
Study 12692749 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril, 20 mg o.d. for two years)
Number of subjects: 22
Study 12692749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9888904 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching patients to identify early symptoms of relapse and seek prompt treatment from health services (7 to 12 individual treatment sessions from a research psychologist plus routine care)
Number of subjects: 69
Study 9888904 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 69
Study 9888904 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching patients to identify early symptoms of relapse and seek prompt treatment from health services
Number of subjects: 69
Study 7741619 — intervention group
Group type: EXPERIMENTAL
Intervention: AC iontophoresis for 4 hours
Number of subjects: 10
Study 7741619 — intervention group
Group type: EXPERIMENTAL
Intervention: AC iontophoresis for 2 hours
Number of subjects: 10
Study 7741619 — intervention group
Group type: COMPARATOR
Intervention: Control patch (not activated)
Number of subjects: 10
Study 1952199 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic suggestions (tape recording predicting smooth recovery)
Number of subjects: 209
Study 1952199 — intervention group
Group type: COMPARATOR
Intervention: Control (blank tape)
Number of subjects: 209
Study 7102768 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of oral sulpiride for 4 days from the third postpartum day
Number of subjects: 96
Study 7102768 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 days from the third postpartum day
Number of subjects: 96
Study 29438156 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity - Cognitive Concerns
Number of subjects: 470
Study 29438156 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity - Physical Concerns
Number of subjects: 470
Study 27467700 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal psychodynamic therapy (FPT)
Number of subjects: 169
Study 27467700 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavior therapy (CBT‐E)
Number of subjects: 169
Study 27467700 — intervention group
Group type: COMPARATOR
Intervention: Optimized treatment as usual (TAU‐O)
Number of subjects: 169
Study 27467700 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 169
Study 23700142 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple plasma amino acid index (API)
Number of subjects: 442
Study 23700142 — intervention group
Group type: COMPARATOR
Intervention: CA125
Number of subjects: 442
Study 22489894 — intervention group
Group type: EXPERIMENTAL
Intervention: BAK-preserved timolol
Number of subjects: 28
Study 22489894 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free timolol
Number of subjects: 28
Study 20298823 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised exercise program including aerobic training, strength training, and group sport
Number of subjects: 147
Study 20298823 — intervention group
Group type: COMPARATOR
Intervention: Submaximal testing with heart rate <140 bpm
Number of subjects: 147
Study 20298823 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal testing with heart rate >=140 bpm
Number of subjects: 147
Study 17532576 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of alcohol
Number of subjects: 213
Study 17532576 — intervention group
Group type: COMPARATOR
Intervention: No alcohol presence
Number of subjects: 213
Study 17532576 — intervention group
Group type: COMPARATOR
Intervention: Resistance type
Number of subjects: 213
Study 17532576 — intervention group
Group type: COMPARATOR
Intervention: Participant gender
Number of subjects: 213
Study 16235869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention (4-6 weeks)
Number of subjects: 136
Study 16235869 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 12022095 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution ultrasonography (HR-US) at closed-mouth position
Number of subjects: 29
Study 12022095 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution ultrasonography (HR-US) at maximum-mouth opening position
Number of subjects: 29
Study 9620110 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 0
Study 9620110 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 9620110 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic interventions (general)
Number of subjects: 0
Study 8092084 — intervention group
Group type: COMPARATOR
Intervention: 0.80 g protein.kg‐1.d‐1
Number of subjects: 12
Study 8092084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62 g protein.kg‐1.d‐1
Number of subjects: 12
Study 8092084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from current and previous studies
Number of subjects: 12
Study 2803624 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 16 weeks
Number of subjects: 85
Study 2803624 — intervention group
Group type: COMPARATOR
Intervention: Nonaerobic exercise (yoga)
Number of subjects: 85
Study 2803624 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 85
Study 4424007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallbladder bile
Number of subjects: 30
Study 4424007 — intervention group
Group type: COMPARATOR
Intervention: Hepatic bile
Number of subjects: 30
Study 4424007 — intervention group
Group type: COMPARATOR
Intervention: Bile from non-functioning gallbladders
Number of subjects: 30
Study 4424007 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile with cholesterol crystals
Number of subjects: 30
Study 4424007 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile analysis
Number of subjects: 30
Study 30681490 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS group
Number of subjects: 102
Study 30681490 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 28625384 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥2 appropriate shocks
Number of subjects: 1268
Study 28625384 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥2 inappropriate shocks
Number of subjects: 1268
Study 28625384 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥2 appropriate ATPs
Number of subjects: 1268
Study 28625384 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥2 inappropriate ATPs
Number of subjects: 1268
Study 28625384 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate or inappropriate ATP/shock
Number of subjects: 1268
Study 25706515 — intervention group
Group type: EXPERIMENTAL
Intervention: New rehabilitation philosophy (new credo)
Number of subjects: 166
Study 23394896 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NT-proBNP
Number of subjects: 772
Study 23394896 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-6
Number of subjects: 772
Study 23394896 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hsCRP
Number of subjects: 772
Study 23394896 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 772
Study 23394896 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 772
Study 23394896 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 772
Study 23394896 — intervention group
Group type: EXPERIMENTAL
Intervention: IP-10
Number of subjects: 772
Study 21263308 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (10% Travasol)
Number of subjects: 10
Study 21263308 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 healthy young males, 22 ± 3 years; 76 ± 15 kg)
Number of subjects: 10
Study 21263308 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body protein breakdown
Number of subjects: 10
Study 17919270 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic supplementation
Number of subjects: 86
Study 17919270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 16945784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing case management intervention
Number of subjects: 1000
Study 16945784 — intervention group
Group type: EXPERIMENTAL
Intervention: Danger Assessment Screen
Number of subjects: 1000
Study 16945784 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine screening questions during pregnancy
Number of subjects: 1000
Study 16945784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of being reported to child protective services
Number of subjects: 1000
Study 12869382 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic infusions of immunoglobulins (Ig)
Number of subjects: 0
Study 12869382 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro with RBC suspensions containing fibrinogen, albumin, and Ig
Number of subjects: 0
Study 12869382 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10708159 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 32
Study 10708159 — intervention group
Group type: COMPARATOR
Intervention: Heated humidified water (HHW)
Number of subjects: 32
Study 9094145 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day selegiline
Number of subjects: 36
Study 9094145 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day selegiline
Number of subjects: 36
Study 9094145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9094145 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (both doses)
Number of subjects: 36
Study 7701235 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 3113244 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol 200 micrograms twice daily
Number of subjects: 32
Study 3113244 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 3113244 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol
Number of subjects: 32
Study 29520867 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 50 μg
Number of subjects: 80
Study 29520867 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine 4 mg
Number of subjects: 80
Study 28794283 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinsulin peptide immunotherapy (intradermally every 2 or 4 weeks for 6 months)
Number of subjects: 0
Study 28794283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26026214 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 58
Study 26026214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23233356 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact with non-attendees offering an appointment to take a smear
Number of subjects: 4000
Study 21052959 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 23
Study 19546387 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg/kg rFVIIa
Number of subjects: 172
Study 19546387 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg/kg rFVIIa
Number of subjects: 172
Study 19546387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 16738287 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 38
Study 16738287 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy surgery
Number of subjects: 38
Study 15517749 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing change procedure
Number of subjects: 133
Study 15517749 — intervention group
Group type: EXPERIMENTAL
Intervention: Reapplied wound-dressing products
Number of subjects: 133
Study 11213933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereavement support group intervention (one 90‐minute group session per week for 10 weeks)
Number of subjects: 0
Study 11213933 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9296310 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocapril (10-40 mg once daily)
Number of subjects: 472
Study 9296310 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (25-100 mg once daily)
Number of subjects: 472
Study 7982016 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine (1.5 g daily, 3 x 500 mg for 6 weeks)
Number of subjects: 14
Study 7982016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14
Study 3549801 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% topical minoxidil
Number of subjects: 58
Study 3549801 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% topical minoxidil
Number of subjects: 58
Study 3549801 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% topical minoxidil
Number of subjects: 58
Study 3549801 — intervention group
Group type: COMPARATOR
Intervention: 0.01% topical minoxidil
Number of subjects: 58
Study 3549801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 30055593 — intervention group
Group type: EXPERIMENTAL
Intervention: Practicing self‐medication
Number of subjects: 382
Study 30055593 — intervention group
Group type: EXPERIMENTAL
Intervention: Having more than three family members in the household
Number of subjects: 382
Study 30055593 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (≥55 years)
Number of subjects: 382
Study 30055593 — intervention group
Group type: EXPERIMENTAL
Intervention: Being smear negative pulmonary tuberculosis
Number of subjects: 382
Study 30055593 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrapulmonary tuberculosis
Number of subjects: 382
Study 30055593 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial visit of general practitioners
Number of subjects: 382
Study 30055593 — intervention group
Group type: EXPERIMENTAL
Intervention: More than one health care visit
Number of subjects: 382
Study 30055593 — intervention group
Group type: EXPERIMENTAL
Intervention: Widowed/divorced patients
Number of subjects: 382